07:00 , Apr 7, 2003 |  BioCentury  |  Finance

1Q Setbacks

1Q Setbacks...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Clinical News

Atgam: Marketed to treat of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation

In a long-term U.S. study in 122 patients, 55% of patients given Atgam plus cyclosporine were alive at 7 years. Data were published in the Journal of the American Medical Association. Pharmacia Corp. (PHA), Peapack,...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Clinical News

ABX-CBL: Phase II/III

The companies discontinued development of ABX-CBL after the compound failed to meet the primary endpoint of increased survival at 180 days compared to Atgam anti-thymocyte globulin. The Phase II/III trial included patients with acute steroid-resistant...
08:00 , Feb 24, 2003 |  BioCentury  |  Finance

Ebb & Flow

Investors typically pay a premium for biotech earnings, largely on the promise of future growth. Thus the fact that...
08:00 , Feb 18, 2003 |  BC Extra  |  Clinical News

Abgenix, SangStat end ABX-CBL development

ABGX and SANG said they will end development of ABX-CBL, an anti- CD147 antibody, after the compound failed to increase survival at 180 days compared to Atgam anti-thymocyte globulin in a Phase II/III trial in...
07:00 , Jul 15, 2002 |  BC Extra  |  Clinical News

SangStat completes Phase II/III GvHD enrollment

SANG completed enrollment in an international Phase II/III study comparing ABX-CBL to Atgam anti-thymocyte globulin in treating steroid-resistant graft-versus-host disease (GvHD) in allogeneic bone marrow transplant patients. SANG said there were 92 evaluable patients. The...
08:00 , Jan 11, 1999 |  BioCentury  |  Strategy

SangStat's bid for critical mass

With the approval of Thymoglobulin , the second major piece of its transplant package, and expected approval of its cyclosporine in Europe, SangStat Medical Corp. believes it has the critical mass to attain significant growth...
07:00 , May 4, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin rabbit anti-thymocyte globulin: NDA submitted; Phase III data presented

Twelve-month results of a Phase III trial of Thymoglobulin in 162 patients showed survival rates were similar to those with Atgam horse anti-thymocyte globulin, and that less recurrent rejection followed after use of the rabbit...
07:00 , May 4, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin rabbit anti-thymocyte globulin: Phase II

Results of a study of Thymoglobulin in inducing immunosuppression in 72 consecutive patients receiving kidneys showed less severe and less frequent rejection as compared to treatment with Atgam (p=0.014). Lymphopenia was more prolonged with Thymoglobulin,...
08:00 , Jan 19, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin anti-thymocyte globulin from rabbits data

A Phase II trial of Thymoglobulin in 72 patients showed significant improvement in acceptance of kidney transplants compared to Atgam horse immunoglobulin. Thymoglobulin reduced rejection episodes by 83 percent. Biopsy-proven rejection was 4.2 percent in...